Where is Bio Usawa located?

Bio Usawa is headquartered in San Francisco, United States.

How many employees does Bio Usawa have?

As of Jun 30, 2026, the latest employee count at Bio Usawa is 12.

Is Bio Usawa a funded company?

Bio Usawa is a funded company, having raised a total of $2.61M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 21, 2024.

When was the latest funding round of Bio Usawa?

Bio Usawa's latest funding was a $***** Seed round on Oct 30, 2025, with participation from 0 investor.

Where does Bio Usawa rank among its competitors?

Bio Usawa ranks 371st amongst 2891 active competitors, of which 986 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Bio Usawa?

Bio Usawa's top competitors include Jazz Pharmaceuticals, Alexion and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Bio Usawa - 2026 Company Profile, Team, Funding & Competitors

Bio Usawa is a seed company based in San Francisco (United States), founded by Richard Chin. It operates as a Developer of immunotherapy for cancer treatment. Bio Usawa has raised $2.61M in funding. The company has 2891 active competitors, including 986 funded and 741 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alexion and Sana Biotechnology.

Company Details

Developer of immunotherapy for cancer treatment. It offers biosimilars and monoclonal antibodies for treatment of blood cancer, immunology, and ophthalmology.

Website: biousawa.com
Email ID: *****@biousawa.com

Key Metrics

Location

San Francisco, United States

Stage

Seed

Total Funding

$2.61M in 3 rounds

Latest Funding Round

Seed, Oct 30, 2025, $*****

Ranked

371^st among 2891 active competitors

Employee Count

12 as on Jun 30, 2026

Similar Companies

Alexion & 614 more

View Bio Usawa's full profile

Bio Usawa has raised a total funding of $2.61M over 3 rounds. Its first funding round was on Feb 21, 2024.

Here is the list of recent funding rounds of Bio Usawa:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 30, 2025	5373797	Seed	5818193	9066545	2337867	6986676
Jan 16, 2025	2837564	Seed	7806830	8173340	3904018	4081544
Feb 21, 2024	1630785	Seed	7940319	8759737	6629823	8719158

Access funding benchmarks and valuations. Sign up today!

View details of Bio Usawa's funding rounds and investors

The founders of Bio Usawa is Richard Chin.

Here are the details of Bio Usawa's key team members:

Richard Chin: Co-Founder of Bio Usawa and founder of 1 other company.
Contact Info: 1 email address

View details of Bio Usawa's Founder profiles and Board Members

Bio Usawa's employee count trend

Bio Usawa has 12 employees as of Jun 26. Here is Bio Usawa's employee count trend over the years:

Uncover Bio Usawa's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bio Usawa include Jazz Pharmaceuticals, Alexion and Sana Biotechnology. Here is the list of Top 10 competitors of Bio Usawa, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
371st	Bio Usawa San Francisco (United States), Seed	Developer of immunotherapy for cancer treatment	$2.61M	-	55/100